Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04511273
Other study ID # Cairo University Hospitals
Secondary ID
Status Not yet recruiting
Phase
First received
Last updated
Start date September 1, 2020
Est. completion date April 1, 2021

Study information

Verified date August 2020
Source Kasr El Aini Hospital
Contact Samer Morsy
Phone 01000908851
Email Samermorsy1@gmail.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

80 female patients evaluated for sexual function after receiving Mirabegron 50 mg once daily for 6 months for treatment of overactive bladder symptoms


Description:

80 female patients evaluated for sexual function after receiving Mirabegron 50 mg once daily for 6 months for treatment of overactive bladder symptoms


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 80
Est. completion date April 1, 2021
Est. primary completion date October 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- any female with overactive bladder symptoms, urgency and urgency incontinence

Exclusion Criteria:

- neurologic abnormalities

- Weak bladder contractility

- Diabetics

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Follow up of female sexual function
Mirabegron 50mg once daily for treatment of overactive bladder symptoms

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Kasr El Aini Hospital

Outcome

Type Measure Description Time frame Safety issue
Primary Sexual function evaluation after 6 months Sexual function evaluation using female sexual function index FSFI 6 months